ATOPIC DERMATITIS: NEW TARGETS OF THERAPY
https://doi.org/10.15690/vsp.v13i4.1087
Abstract
Treatment of atopic dermatitis (AD) is most often based on the relief of symptoms. Two fundamental basis of AD — dry skin and itching — determine the main objectives of treatment of this chronic inflammatory diseases of the skin. With this purpose, the patients are recommended to use moisturizers (emollients) and topical anti-inflammatory drugs — corticosteroids, and/or calcineurin inhibitors. However, there are studies conclusively proving the existence of subclinical inflammation associated with impaired barrier function of
the skin, production of cytokines and infiltration of lymphocytes. The new strategy of treatment — proactive therapy aimed at achieving control and maintenance of remission of atopic dermatitis. This will allow you to achieve faster control the symptoms of AD and to reduce the risk of recurrence of the disease.
the skin, production of cytokines and infiltration of lymphocytes. The new strategy of treatment — proactive therapy aimed at achieving control and maintenance of remission of atopic dermatitis. This will allow you to achieve faster control the symptoms of AD and to reduce the risk of recurrence of the disease.
Supporting agencies: “Bayer”, CJSC.
About the Author
D. Sh. Macharadze
People’s Friendship University of Russia, Moscow
Russian Federation
Macharadze Dali Shotaevna, PhD, professor of the Department of Allergology and Clinical Immunology
Russian Federation
Macharadze Dali Shotaevna, PhD, professor of the Department of Allergology and Clinical Immunology
References
1. Thomsen S. Atopic dermatitis: natural history, diagnosis, and treatment. ISRN Allergy. 2014; 14: 354–360.
2. Eichenfield L., Totri C. Optimizing outcomes for paediatric atopic dermatitis. Brit. J. Dermatol. 2014; 170 (Suppl. 1): 31–37.
3. Irvine А., McLean W., Leung D. Filaggrin mutations associated with skin and allergic diseases. N. Engl. J. Med. 2011; 14: 1315–1327.
4. Stalder J., Taieb A., Atherton D. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1993; 186: 23–31.
5. Hanifin J., Thurston M., Omoto M., Cherill R., Tofte S., Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp. Dermatol. 2001; 10: 11–18.
6. Ring J., Alomar A., Bieber T. Guidelines for treatment of atopic eczema (atopic dermatitis) — part I. J. Eur. Acad. Dermatol. Venerol. 2012; 26: 1045–1060.
7. Lio P., Lee M., LeBovidge J., Timmons K., Schneider L. Clinical Management of Atopic Dermatitis: Practical Highlights and Updates from the Atopic Dermatitis Practice Parameter 2012. J. Allergy Clin. Immunol. Pract. 2014; 2 (4): 361–369.
8. Peserico A., Stadtler G., Sebastian M. et al. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Brit. J. Dermatol. 2008; 158: 801–807.
9. Korting H., Schollmann C. Topical fluticasone propionate: intervention and maintenance treatment options of atopic dermatitis based on a high therapeutic index. J. Eur. Acad. Dermatol. Venerol. 2012; 26: 133–140.
10. El-Batawy M., Bosseila M., Mashaly M., Hafez V. Topical calcineurin inhibitors in atopic dermatitis: A systematic review and metaanalysis. J. Dermatol. Sci. 2009; 54: 76–87.
Review
For citations:
Macharadze D.Sh. ATOPIC DERMATITIS: NEW TARGETS OF THERAPY. Current Pediatrics. 2014;13(4):70-73. (In Russ.) https://doi.org/10.15690/vsp.v13i4.1087
Views:
930
Email this article 
